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PURPOSE. To determine if vitreous levels of the pro-fibrotic cytokine transforming growth
factor beta2 (TGF-b2) and its opposing regulator decorin predict subsequent proliferative
vitreoretinopathy (PVR) development in patients with rhegmatogenous retinal detachment
(RRD).
METHODS. We examined the effect of TGF-b2 and decorin on epithelial-mesenchymal transition
(EMT) and collagen expression in vitro using ARPE-19 cells, and we analyzed extracellular
matrix marker expression in PVR membrane and internal limiting membrane patient samples.
We performed a prospective noninterventional cohort study, recruiting 125 patients
undergoing vitrectomy for RRD and macular hole surgery, measured vitreous levels of TGF-
b2 and decorin by ELISA, and followed them up for 6 months. Patients who did not develop
PVR were compared to those who did, in order to determine whether vitreous TGF-b2 and
decorin levels predicted PVR development.
RESULTS. In vitro, TGF-b2 induced EMT and collagen production. Decorin strongly inhibited
EMT and collagen production at high levels. PVR membranes expressed high levels of fibrosis-
associated proteins, consistent with EMT. Vitreous TGF-b2 levels were unchanged between
patients with macular holes and RRD who did or did not subsequently develop PVR. Average
decorin levels were higher in the vitreous of RRD patients who subsequently developed PVR
compared to those who did not, but at the measured vitreous concentrations (1–2 lg/mL),
decorin did not demonstrate an in vitro inhibitory effect on EMT.
CONCLUSIONS. In vitro, high concentrations of decorin inhibited EMT and fibrosis. At the levels
seen in human vitreous, decorin did not prevent fibrosis or EMT in vitro, and higher initial
vitreous decorin levels were associated with the development of postoperative PVR after
vitrectomy to treat RRD, but did not reliably predict the outcome.
Keywords: proliferative vitreoretinopathy, vitreous humor, epithelial to mesenchymal
transition, transforming growth factor beta 2, retinal detachment
Proliferative vitreoretinopathy (PVR) describes a retinalscarring process that occurs in 5% to 10% of rhegmatog-
enous retinal detachment (RRD) patients and up to 50% of open
globe injury patients and is the main cause of surgical failure
after retinal detachment surgery.1 Clinically, PVR is character-
ized by the growth and contraction of cellular fibrotic
membranes within the vitreous, retina, and subretinal space,
which exert traction, open treated breaks, create new breaks,
and cause redetachment or distort the macula. Although the
clinical manifestations of PVR are wide, they share a common
sequence of underlying cellular responses that are associated
with RRD and vitreous changes, and eyes with existing PVR are
at higher risk of increased retinal cell proliferation after repeat
vitreoretinal surgery.2
The TGF-b superfamily modulates cell growth, inflamma-
tion, matrix synthesis, and apoptosis.3 TGF-b exists in two main
forms (TGF-b1 and TGF-b2), with TGF-b2 being the predom-
inant form in the posterior segment of human eyes.4,5 Both in
vitro and in vivo, TGF-b isoforms regulate synthesis and
degradation of extracellular matrix (ECM) proteins, causing
increased collagen accumulation and fibrosis,6 which makes
them key candidate prognostic biomarkers for PVR develop-
ment and important therapeutic targets for prophylaxis and
treatment of PVR. TGF-b is secreted as part of a latent
complex,7 cleaved into its active form by RPE-derived
thrombospondin-1. Activated TGF-b causes RPE cells to
undergo epithelial-mesenchymal transition (EMT) to become
fibroblasts, to produce type 1 collagen, and to become
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myofibroblast-like in the absence of normal cell-cell or cell-
matrix interactions in vitro.8–10 There are separate TGF-b1 and
TGF-b2 receptors, though many of these are cross-reactive.11,12
Several studies have found elevated TGF-b2 levels in vitreous
samples from patients with PVR,5,13,14 suggesting a role in
pathogenesis and potential as a predictive biomarker for PVR
development.
Decorin is a small leucine-rich proteoglycan matrix-constit-
uent that opposes the actions of TGF-b by interacting with
TGF-b and other cytokines. Decorin modulates matrix metal-
loproteinase (MMP) activity by increasing levels of plasmino-
gen15 favoring higher ECM turnover leading to ECM
degradation. Decorin elevates MMP2 and MMP9 levels, reduces
fibronectin and laminin deposition,16 and attenuates fibrosis in
animal models of many pathological conditions, including
proliferative vitreoretinopathy,17 renal fibrosis,18 lung fibro-
sis,19 juvenile communicating hydrocephalus,20 and spinal
cord injury.5,21
We hypothesized that TGF-b would induce EMT in RPE cells
in vitro and that decorin would oppose EMT. We also predicted
that, in humans, high vitreous TGF-b and low vitreous decorin
levels would predict the subsequent development of PVR in
patients with RRD and that RRD patients would have higher
vitreous TGF-b levels than patients with macular holes (MH).
We investigated the effects of TGF-b2 and decorin on ARPE-
19 cell EMT in vitro, we looked for immunohistologic evidence
of EMT in human PVR membranes, and we performed a
prospective noninterventional cohort study of MH and RRD
patients, following them up for 6 months to determine PVR
development. Eyes with macula holes do not develop
intraocular scarring despite having a retinal break and were
used as a control for retinal detachment cases where there is a
retinal break and a risk of intraocular scarring.
METHODS
Cell Culture
ARPE-19 cells (CRL-2302; ATCC, Manassas, VA, USA) were
grown in Dulbecco’s modified Eagle’s medium/F12 supple-
mented with 100 U/mL penicillin/streptomycin and 10% heat-
inactivated fetal bovine serum. Cells were incubated at 378C in
a humidified environment containing 5% CO2. For real-time
PCR (qPCR), 300,000 cells/well were seeded in a six-well plate,
incubated overnight, and washed with PBS to remove FBS.
Cells were then either treated with serum plus medium, 10 ng/
mL transforming growth factor b2 (TGF-b2) in serum-free
(serum) media or givenserum medium only. After 72 hours,
cells were treated with decorin concentrations from 1 ng/mL
up to 100 lg/mL with and without the previous treatment of
TGF-b2 inserum medium and left for a further 72 hours, after
which they were harvested. All cell cultures were performed in
triplicate experiments, and each experiment was repeated on
three independent occasions (n¼ 3 repeats in total).
Real-Time Quantitative qPCR Analysis
RNA was extracted from ARPE-19 cells using a purification mini
kit according to the manufacturer’s instructions (Qiagen
RNeasy; Qiagen, Hilden, Germany). RNA was reverse tran-
scribed using a cDNA synthesis kit (Sensifast; Bioline, London,
UK). qPCR was carried out using a fluorescent dye (SYBR
Green Master Mix; Applied Biosystems, Foster City, CA, USA) in
20-lL reactions using a multicolor qPCR detection system (iQ5;
Bio-Rad, Watford, UK). Primers were optimized using a seven-
point standard curve (Supplementary Table S1). Genes of
interest were normalized to human GAPDH using the DDct
method based on primer efficiencies (HK-SY-hu-1200; Primer-
design, Camberley, UK). Data are presented normalized to TGF-
b2-treated groups or the serum group.
Bromodeoxyuridine (BrdU) ELISA
The ELISA was performed as previously described.22 Please see
Supplementary Methods.
Clinical Studies
This cohort study was approved by the Solihull National
Research Ethics Service committee and the use of tissue for
immunohistochemistry by Arden Tissue Bank. The study
was conducted in accordance with the Declaration of
Helsinki.
We included patients in the cohort study who were
undergoing vitrectomy for new RRD, MH, and established
PVR and who were capable of consenting to participation. We
excluded patients who had any previous vitreoretinal surgery
(except for the established PVR group) or were aged under
10.
Tissue for immunohistochemistry was collected with
consent from patients who were undergoing vitrectomy with
membrane peel for PVR or internal limiting membrane (ILM)
peel for MH repair. Total number of samples collected for each
group is represented in Supplementary Figure S1.
Sample Collection
Vitreous was collected into a 5-mL syringe through an
unprimed cutter at the start of surgery in the largest safe
volume possible, ranging between 0.5 and 2 mL, before the
infusion was turned on. Samples were refrigerated for up to 4
hours before being centrifuged at 12,300 g for 10 minutes
and the supernatant collected and frozen at 808 until
analysis.
3, 3-Diaminobenzidine (DAB) Staining of Human
PVR and ILM Tissues
The membranes were removed from fixative and embedded in
warm agar. Set agar blocks were processed into paraffin wax
using a tissue processor (study reference: 17-0477) (Path-
Center; Shandon Scientific, Runcorn, UK).
Blocks were sectioned at 5 lm using a microtome (Bright
5040; Bright Instruments, Luton, UK) and placed onto slides
(Superfrost; Thermo Fisher Scientific UK Ltd, Loughborough,
UK) and dried overnight at 508C. Slides were stained by DAB
according to the manufacturer’s instructions (Leica, Wetzlar,
Germany). Please see Supplementary Methods.
TGF-b2 and Decorin ELISA
Sandwich ELISAs (R&D Systems, Minneapolis, MN, USA) were
used to measure TGF-b2 and decorin levels in human vitreous
samples after vitreoretinal surgery. Total number of samples
used for each assay is shown in Supplementary Figure S1.
Vitreous samples were normalized according to volume as the
protein content was below the level of sensitivity. TGF-b2 and
decorin ELISAs were performed in accordance with manufac-
turer’s instructions. Please see Supplementary Methods.
Statistics
Averages are displayed as means plus or minus standard error
in text and figures.
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Sample size calculation was performed with statistical
power analysis software (G*Power, v. 3.1.4; Kiel University,
Kiel, Germany) for a two-sample t-test with an expected
allocation of one PVR case per 10 retinal detachment cases.
Pilot data from 46 patients with retinal detachment and 16
patients with MH indicated that vitreous levels of decorin were
(1463 6 219 vs. 261 6 57 pg/mL). Power calculation
performed in G*Power for a two-sample t-test indicated that
we would require group sizes of 7 and 71 patients to have 80%
power to detect the observed difference.
Our prespecified analysis was a t-test to compare vitreous
decorin levels between patients with retinal detachment who
did and who did not develop postoperative PVR; as variances
were not homogeneous between groups, the PVR group was
smaller and had a higher mean and a higher variance, a Mann-
Whitney U statistic is also presented. For all other analyses of
ELISA and PCR data, sample means were compared by 1-way
ANOVA with Bonferroni-corrected post-hoc tests. For ELISA
data, variances were again nonhomogeneous, with larger
variances associated with smaller sample sizes (which tends
to cause overly conservative P values), so Kruskal-Wallace
results are also given. P values were Bonferroni corrected
within experiments.
RESULTS
ARPE-19 Cell Cultures
To characterize the effects of decorin on RPE cells we
developed an in vitro model of RPE EMT. Serum-free ARPE-19
cell cultures expressed low levels of mRNA for connective
tissue molecules laminin, fibronectin, and collagen type I and
higher levels of the RPE markers RPE65 and CK8. Consistent
with not having undergone EMT and not being in a pro-fibrotic
state, they also expressed low levels of vimentin and a-SMA
(Fig. 1). In comparison toserum, cultures supplemented with
serum (þserum) had increased expression of laminin (P <
0.001), fibronectin (P < 0.05), and collagen I (P < 0.004) and
reduced expression of the RPE markers CK8 (P < 0.013) and
RPE65 (P < 0.035). Vimentin and a-SMA levels were not
significantly altered with serum. Serum-free cultures were
therefore used to examine the effect of TGF-b2 and decorin on
ARPE-19 cells.
TGF-b2 In Vitro
Compared to serum, 10 ng/mL of TGF-b2 increased mRNA
levels of fibronectin (P < 0.05, Fig. 1A), laminin (P < 0.001,
Fig. 1B), collagen I (P < 0.05, Fig 1C), a-SMA (P < 0.03) and
decreased CK8 (P < 0.017), which is consistent with an EMT
phenotype. However, RPE65 and vimentin expression were
not significantly altered with TGF-b2 treatment when com-
pared toserum control. TGF-b2 at 10 ng/mL did not affect its
own expression or that of decorin (Supplementary Fig. S2).
Cell Culture Effects of Decorin
ARPE-19 cellsserum were treated with decorin in the range of
1 ng/mL to 100 lg/mL. There was a strong overall effect of
decorin supplementation on laminin, fibronectin, a-SMA, and
vimentin (Fig. 2). Bonferroni post-hoc testing found no
evidence that mRNA expression levels of laminin, fibronectin,
a-SMA, and vimentin (Fig. 2) were affected by decorin
treatment in the range of 1 to 100 ng/mL. However, decorin
concentrations higher than 100 ng/mL reduced fibronectin
expression (1 lg/mL [P < 0.002], 10 lg/mL [P < 0.02], and
100 lg/mL [P < 0.001]), laminin (10 lg/mL [P < 0.048], 100
lg/mL [P < 0.029]), and vimentin (100 lg/mL [P < 0.009]). a-
SMA levels were not significantly downregulated when
compared to the serum control, but high-concentration
decorin supplementation did reduce a-SMA expression com-
pared to the low concentration (P < 0.001). There was weak
evidence that collagen I expression was reduced by an
increasing concentration of decorin. CK8 levels were upregu-
lated by 1 lg/mL of decorin (P < 0.046) and then reduced at
100 lg/mL (P < 0.045) decorin when compared to 1 lg/mL.
RPE65 levels showed a weak evidence of a trend similar to that
FIGURE 1. An in vitro model of EMT in ARPE-19 cells in the presence of serum, without serum, and 10 ng/mL TGF-b2 as characterized by qPCR.
Removal of serum from cultures reduced the mRNA expression of EMT markers fibronectin (A), laminin (B), collagen I (C), a-SMA (D) with no
alteration in vimentin (E), and an increase in the expression of epithelial cell markers CK8 (F), RPE65 (G). The addition of 10 ng/mL of TGF-b2 led to
increased expression of EMT markers and a reduction in epithelial marker expression, which is consistent with an EMT phenotype. Data are
presented as a fold change over GAPDH. Each group is representative of n¼3 with three experimental repeats. Data were analyzed using the 1-way
ANOVA where *P < 0.05, **P < 0.01, ***P < 0.001.
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seen with CK8. Decorin did not regulate its own expression,
but did reduce TGF-b2 expression (Supplementary Fig. S2).
Cell Culture Effects of TGF-b2 and Decorin
Serum-free cultures of ARPE-19 cells were treated with 10 ng/
mL of TGF-b2 for 3 days followed by 3 days with or without
decorin in the range of 1 to 100 lg/mL. BrdU analysis did not
show evidence of toxicity in terms of reduced proliferation
with TGF-b2 and decorin supplementation in the dose-ranges
studied (Supplementary Fig. S3). The addition of decorin at
concentrations of 10 to 100 lg/mL abrogated TGF-b2-induced
upregulation of fibronectin (Fig. 3A; P < 0.001), laminin (Fig.
3B; P < 0.001), collagen I (Fig. 3C; P < 0.001), a-SMA (Fig. 3D;
P < 0.001), and vimentin (Fig. 3E; P < 0.001). No changes
were seen in CK8 expression; however, RPE65 expression
increased at 1 ng/mL (P < 0.001) and decreased at higher
concentrations of decorin.
PVR and ILM Staining
Immunohistochemical analysis of human ILM and PVR
membrane staining showed strong staining for fibronectin
and collagen I (Fig. 4A[i], [iv] PVR tissue; Fig. 4B[i], [iv] ILM
tissue). Laminin had greater levels of staining in the PVR tissue
(Fig. 4A[i]) with little staining observed in the ILM tissue( Fig.
4B[ii]). Vimentin is present in both tissues but is stronger in the
PVR membranes (Fig. 4A[v], Fig. 4B[v]). Very low levels of a-
SMA, RPE65, and CK8 immunostaining were seen in the PVR
and ILM (Fig. 4A[iii], [vi], [vii]; Fig. B[iii], [vi), [vii]).
FIGURE 2. mRNA expression analysis of EMT markers in ARPE-19 cells in the presence of low- and high-dose decorin only. ARPE-19 cells were
serum starved and treated with decorin in the range of 1 ng/mL to 100 lg/mL for 3 days. The addition of increasing concentrations of decorin led to
significant decreases in the mRNA expression of fibronectin (A), laminin (B), collagen I (C), a-SMA (D), vimentin (E). Decorin doses led to increases
in the epithelial marker CK8 (F), which then decreased at the highest does of 100 lg/mL. Decorin did not significantly alter the expression of RPE65
(G). Data are presented as a fold change over GAPDH. Each group is representative of n¼3 with three experimental repeats. Data were analyzed by
1-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001.
FIGURE 3. Decorin inhibition of EMT induced in ARPE-19 cells with 10 ng/mL TGF-b2. ARPE-19 cells were serum starved and treated with 10 ng/mL
of TGF-b2 for 3 days, after which they were treated with decorin in the range of 1 ng/mL to 100 lg/mL for 3 days. qPCR analysis for mRNA
expression revealed an increase of EMT markers with TGF-b2 treatment, which was significantly downregulated with a dose-dependent increase of
decorin treatment for fibronectin (A), laminin (B), collagen I (C), a-SMA (D); vimentin (E), CK8 (F), and RPE65 (G) were then analyzed. Data are
presented as a fold change over GAPDH. Each group is representative of n ¼ 3 with three experimental repeats. Data were analyzed by 1-way
ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001.
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Vitreous Decorin
We included 85 patients with retinal detachment (of whom 14
developed PVR), 33 patients with MH, and seven with PVR at
presentation (Supplementary Fig. S1). Primary analysis showed
there was some evidence that vitreous decorin levels were
higher in patients with retinal detachment who did develop
postoperative PVR (2391 6708 pg/mL, SD 1873 pg/mL) than
in those who did not (1232 6 201 pg/mL, SD 1694 pg/mL)
develop postoperative PVR (t-test P¼ 0.038; Mann-Whitney U
test ¼ 0.075). There was weak evidence that total vitreous
decorin levels increased between MH (962 6 252 pg/mL),
RRD, and those patients who went on to develop postoper-
ative PVR (P¼ 0.09, 1-way ANOVA; P¼ 0.075, Kruskal-Wallace;
Fig. 5). Patients with established PVR (1352 6 669) had
vitreous decorin levels similar to that of RRD patients (1231 6
201 pg/mL) and MH (962 6 252 pg/mL) patients. The weak
association between higher levels of decorin in detachment
and those patients who developed postoperative PVR suggests
that vitreous decorin levels do not reliably predict the
development of PVR but does support the hypothesis that
vitreous decorin biology is altered in RRD and PVR, even if the
increase in expression is variable.
Vitreous TGF-b
Vitreous TGF-b levels were measured in the same patients as
was decorin. Vitreous levels of TGF-b1 were undetectable by
ELISA. Total vitreous TGF-b2 in patients operated for RRD (651
6 69 pg/mL) and MH (598 6 81 pg/mL) was not different
between any of the groups (Fig. 5), including between RRD
patients with an uncomplicated postoperative course, those
who went on to develop PVR (685 6 99 pg/mL), and those
with established PVR (869 6 224 pg/mL). Active TGF-b2 levels
were low and similar for all groups (RRD 33 6 12 pg/mL, MH
38 6 14 pg/mL, developed PVR 45 6 14 pg/mL, established
PVR 62 6 24 pg/mL).
DISCUSSION
In vitro TGF-b2 causes EMT and fibrosis, while decorin is an
antifibrotic agent that drives ARPE-19 cells away from a fibrotic
phenotype, with downregulation of the same markers of EMT
expressed by human PVR membranes. In vivo, we assessed
vitreous decorin and TGF-b2 levels in patients with retinal
detachment who went on to develop PVR and those who did
not and compared these to patients undergoing MH surgery.
There was weak evidence of a relationship between the
subsequent development of PVR and vitreous decorin levels,
with higher levels in RRD compared to MH patients and levels
higher still in patients who subsequently developed PVR. The
weak relationship and high variability suggest that vitreous
decorin at the time of retinal detachment repair would be an
unreliable biomarker for PVR development, although the
finding may be more mechanistically important, and it may
be that a larger study would have had greater power to robustly
demonstrate this effect. The absence of a reliable causative
relationship from a single cytokine is perhaps not surprising
given that PVR is a complex and multifactorial condition and
probably represents the end point of a number of different
disease processes. As an antifibrotic cytokine, the altered
decorin levels may represent a reaction to the exaggerated pro-
fibrotic response to retinal detachment seen in PVR.
Before PVR occurs, a retinal break usually exposes RPE cells
to vitreous. The subsequent RPE fibrosis with epiretinal,
subretinal, and vitreous membrane formation suggests the
presence of EMT activators within the vitreous.23 While the
source of these activators is not known, the TGF-b superfamily
of growth factors plays an important role as an EMT inducer in
PVR.24–26 All three isoforms are present in the eye25,27;
however, TGF-b1 levels are low or undetectable in the vitreous
in comparison to TGF-b2 levels, which are much higher.4,5,26
This is supported by our results.
Altered TGF-b2 levels have been demonstrated in estab-
lished PVR and in patients with RRD who subsequently
FIGURE 4. Representative images of EMT protein in human PVR tissue and human ILM. Tissue was collected from patients and paraffin embedded.
DAB staining was carried out to measure protein in PVR tissue (A) (i) fibronectin, (ii) laminin, (iii) a-SMA, (iv) collagen I, (v) vimentin, (vi) RPE65,
(vii) CK8, and in ILM tissue (B) (i) fibronectin, (ii) laminin, (iii) a-SMA, (iv) collagen I, (v) vimentin, (vi) RPE65, (vii) CK8 in ILM tissues. Brown
staining is representative of positive protein expression with strong staining in the PVR and ILM for ECM markers such as fibronectin, collagen I, and
vimentin and low levels of expression for the epithelial markers RPE65 and CK8. Hemotoxylin was used as a counterstain to stain the nuclei in blue.
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developed PVR, but this does not reliably and independently
predict subsequent PVR development.5,13,28 In our patients,
neither latent nor active vitreous TGF-b2 levels separated RRD
from MH patients or patients with established PVR and did not
predict subsequent PVR development at the time of initial
RRD. The narrow confidence intervals for TGF-b2 levels
suggest that this negative finding is robust, and our study is
not underpowered with respect to this outcome. Additionally,
active TGF-b2 levels were significantly lower than latent TGF-
b2 levels in all groups. Therefore, given that TGF-b2 is
associated with fibrosis, our data are consistent with RPE
EMT caused by increased RPE exposure to vitreous TGF-b2
after migration into the vitreous cavity, rather than elevated
vitreous levels per se. It is also possible that TGF-b2 levels vary
during the course of PVR development, and our relatively low
measurements preceded a rise in TGF-b2 levels in our RRD
patients, observed after its effect in the established PVR cases.
Decorin antagonizes TGF-b and has independent anti-
fibrotic properties. It presents itself as a strong therapeutic
candidate to inhibit TGF-b2-induced RPE fibrosis.29 It prevents
fibrosis by directly binding and sequestering TGF-b and by
inhibiting cell migration, proliferation, and extracellular matrix
production.30,31 Intravitreal injections of decorin reduced
macroscopic fibrosis in a rabbit PVR model.17 It is therefore
surprising that increased (not reduced) vitreous decorin levels
were associated with PVR. We characterized the role of
decorin in RPE EMT by developing an in vitro model of TGF-
b2-induced ARPE-19 cell EMT. TGF-b2 induced expression of a
wide selection of ECM and EMT markers combined with
reduced epithelial marker expression in ARPE-19 cells. The
mRNA changes in vitro reflected the human protein changes
seen by immunohistochemistry, supporting the validity of this
model.
The rate of PVR in our cohort was 11% (14/125; 95%
confidence interval: 6.5%–18.4%), which is toward the upper
end of published rates (5.1%–11.7%).32 The Birmingham and
Midland Eye Centre is a regional tertiary referral center for
vitreoretinal surgery and it may be that the case mix in our
institution has a high risk of PVR. As the study was not
designed to evaluate PVR rates, we cannot comment on the
extent of preoperative risk factors that may affect these rates in
our cohort.
We treated cells with decorin at a range of concentrations to
compare physiologic vitreous levels and those that would
occur after therapeutic supplementation. At low, physiologic
concentrations, decorin did not inhibit the production of ECM
markers induced by TGF-b2 but did induce the expression of
RPE65, a specific RPE marker. Decorin supplementation at
higher concentrations (>1–10 lg/mL) significantly abrogated
TGF-b2-induced upregulation of ECM and EMT markers,
confirming the feasibility of decorin as an antifibrotic agent.
The effects of decorin on CK8 expression after TGF-b2-induced
upregulation of ECM were less pronounced. The variable
effects of decorin at different concentrations suggest a biphasic
dose-response, which may be related to steric hindrance for
some effects at concentrations above 1 lg/mL33 or to a
decorin-independent TGF-b pathway.34
In burn patients, we have found that serum decorin
correlates with injury severity,35 suggesting that its expression
may be an injury response, with more severely damaged
retinae expressing more decorin, though not at levels sufficient
to prevent intraocular fibrosis. Unfortunately, we do not have
sufficient clinical data to test this hypothesis. The most
effective antifibrotic concentrations were in the microgram
per milliliter range, suggesting that any therapeutic interven-
tion to prevent or treat PVR should use decorin aiming for
vitreous concentrations >1 lg/mL.
An important feature of PVR is the proliferation of RPE cells
to produce epiretinal membranes. Our results suggest that this
proliferation is not initiated by elevated vitreous TGF-b2,
consistent with current literature suggesting that TGF-bs are
not involved in the initiation of proliferation.9,28 Additionally,
decorin, which antagonizes TGF-b, did not affect RPE
proliferation. Decorin has a variable antiproliferative effect,
which differs between cell types.29,36 As the study was
restricted in sample collection by clinical treatment, it was
not possible to carry out more relevant serial assays that may
have highlighted variations in decorin levels over time.
The data presented show that vitreous levels of TGF-b2 and
decorin in isolation are unlikely to be useful predictors of
disease at the stages that we assayed, although elevated
vitreous decorin may represent a response to injury. Our in
vitro analysis shows that TGF-b2 induces EMT in human RPE
cells and that decorin reverts the cells to a more RPE-like
FIGURE 5. Decorin and TGF-b2 levels in the vitreous in patients who had MH and retinal detachment, and those who went on to develop PVR and
those with PVR at presentation. TGF-b2 levels were not significantly different between the groups, with active levels in the lower range of 33 to 63
pg/mL. Latent levels of TGF-b2 were higher, 598 to 869 pg/mL, but with no significant changes between the groups. Decorin levels were higher and
showed a nonsignificant increase in the developed PVR group. Number of patient samples for the decorin ELISA: MH, n ¼ 33; RRD, n ¼ 71;
developed PVR, n¼ 14; PVR at presentation, n¼ 7. Number of patient samples for the latent and active TGF-b2 ELISA: MH, n¼ 21; RRD, n¼ 62;
developed PVR, n ¼ 13; PVR at presentation, n ¼ 6. Data were analyzed using the t-test and the Mann-Whitney U test with a Levine’s test for
homogeneity of variances.
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phenotype, meaning that decorin may have potential as part of
a clinical treatment strategy for PVR.
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